Stock listing
LSE:AVCT Avacta Group PLC Share Price
Home listing (LSE) of Avacta Group PLC
Follow Avacta Group PLC into a list and get an email when it puts out news.
Share price · LSE:AVCT
59.00p GBX (pence) +2.20 (+3.9%)
Close on Nov 20, 2026
- Day range
- 59.00p – 63.00p GBX (pence)Nov 20, 2026
- Volume
- 2.05M sharesNov 20, 2026
- Market cap
- £258.2M GBPAt the close on Nov 20, 2026 · price × 437.6M shares outstanding
- 52-week range
- 48.00p – 92.00p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £1.22M GBPMedian day 1.38M shares · 3 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:AVCT · Home | 59.00p GBX (pence) | +2.20 (+3.9%) | 2,050,020 | 60.16p | 63.00p | 59.00p | 56.80p | Close on Nov 20, 2026 |
| OTC:AVCTF | $0.77 USD | 0.00 (0.0%) | — | $0.77 | $0.77 | $0.77 | $0.77 | Close on Nov 6, 2026 |
| Frankfurt:RTQ1 | €0.705 EUR | +0.035 (+5.2%) | — | €0.705 | €0.705 | €0.705 | €0.670 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:AVCT · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 59.00p | +2.20 | +3.9% | 60.16p | 63.00p | 59.00p | 2,050,020 | |
| 56.80p | -0.20 | -0.4% | 56.58p | 59.00p | 56.00p | 1,434,281 | |
| 57.00p | -0.10 | -0.2% | 56.95p | 58.00p | 56.00p | 1,169,757 | |
| 57.10p | -1.90 | -3.2% | 58.43p | 60.00p | 56.00p | 797,066 | |
| 59.00p | -2.60 | -4.2% | 59.25p | 60.00p | 56.00p | 1,350,702 | |
| 61.60p | +1.90 | +3.2% | 60.00p | 63.00p | 58.00p | 2,041,442 | |
| 59.70p | +5.70 | +10.6% | 54.44p | 60.00p | 53.50p | 5,136,557 | |
| 54.00p | +0.60 | +1.1% | 52.89p | 54.50p | 52.00p | 3,107,309 | |
| 53.40p | -0.40 | -0.7% | 54.00p | 55.00p | 52.60p | 2,157,191 | |
| 53.80p | -1.80 | -3.2% | 55.20p | 56.00p | 53.00p | 5,762,517 | |
| 55.60p | -1.90 | -3.3% | 56.90p | 58.00p | 55.20p | 3,985,363 | |
| 57.50p | 0.00 | 0.0% | 58.00p | 58.50p | 55.00p | 5,808,991 | |
| 57.50p | -1.20 | -2.0% | 58.65p | 60.00p | 56.68p | 2,615,665 | |
| 58.70p | -1.80 | -3.0% | 60.25p | 61.00p | 58.00p | 2,168,626 | |
| 60.50p | -0.50 | -0.8% | 61.00p | 61.00p | 60.00p | 833,122 | |
| 61.00p | -0.50 | -0.8% | 61.68p | 62.00p | 60.45p | 712,501 | |
| 61.50p | 0.00 | 0.0% | 61.74p | 62.00p | 61.00p | 805,573 | |
| 61.50p | -1.00 | -1.6% | 62.80p | 63.00p | 60.00p | 2,234,097 | |
| 62.50p | -0.80 | -1.3% | 65.39p | 66.00p | 62.00p | 1,076,398 | |
| 63.30p | -0.80 | -1.2% | 65.35p | 67.00p | 63.00p | 1,371,247 | |
| 64.10p | -1.60 | -2.4% | 65.50p | 66.00p | 63.90p | 913,349 | |
| 65.70p | -2.60 | -3.8% | 67.50p | 69.00p | 65.00p | 1,443,970 | |
| 68.30p | +0.30 | +0.4% | 68.00p | 70.00p | 67.00p | 1,979,351 | |
| 68.00p | +1.00 | +1.5% | 66.50p | 69.00p | 66.00p | 1,623,292 | |
| 67.00p | +2.00 | +3.1% | 64.00p | 67.00p | 64.00p | 3,643,200 | |
| 65.00p | +0.80 | +1.2% | 63.50p | 65.00p | 62.55p | 1,435,313 | |
| 64.20p | +0.70 | +1.1% | 63.50p | 64.20p | 62.00p | 1,257,890 | |
| 63.50p | -0.50 | -0.8% | 63.50p | 65.00p | 62.33p | 1,195,897 | |
| 64.00p | -1.50 | -2.3% | 65.50p | 66.00p | 63.25p | 1,379,668 | |
| 65.50p | +1.50 | +2.3% | 65.00p | 68.00p | 63.00p | 2,555,031 | |
| 64.00p | +0.50 | +0.8% | 63.50p | 67.76p | 62.00p | 4,588,047 | |
| 63.50p | -4.50 | -6.6% | 68.50p | 69.00p | 63.22p | 2,974,506 | |
| 68.00p | -4.00 | -5.6% | 68.50p | 70.00p | 66.00p | 4,698,688 | |
| 72.00p | 0.00 | 0.0% | 72.00p | 72.00p | 72.00p | 0 | |
| 72.00p | 0.00 | 0.0% | 72.00p | 72.00p | 72.00p | 0 | |
| 72.00p | 0.00 | 0.0% | 72.00p | 72.00p | 72.00p | 0 | |
| 72.00p | 0.00 | 0.0% | 72.00p | 72.00p | 72.00p | 612,341 | |
| 72.00p | -0.50 | -0.7% | 72.50p | 74.00p | 71.00p | 614,155 | |
| 72.50p | -0.30 | -0.4% | 74.00p | 75.00p | 72.00p | 532,003 | |
| 72.80p | -1.20 | -1.6% | 75.50p | 77.00p | 70.73p | 1,880,265 | |
| 74.00p | -1.00 | -1.3% | 74.50p | 75.00p | 73.00p | 358,933 | |
| 75.00p | 0.00 | 0.0% | 75.00p | 76.00p | 72.94p | 748,154 | |
| 75.00p | -3.00 | -3.8% | 78.00p | 79.00p | 74.00p | 1,081,422 | |
| 78.00p | 0.00 | 0.0% | 78.00p | 81.00p | 76.00p | 1,156,082 | |
| 78.00p | +2.00 | +2.6% | 75.50p | 80.00p | 75.00p | 1,335,884 | |
| 76.00p | -2.60 | -3.3% | 79.00p | 81.00p | 74.00p | 3,085,032 | |
| 78.60p | -1.40 | -1.8% | 84.50p | 88.00p | 78.00p | 7,733,552 | |
| 80.00p | +4.50 | +6.0% | 76.00p | 80.80p | 74.00p | 4,504,015 | |
| 75.50p | +2.50 | +3.4% | 73.00p | 77.68p | 72.00p | 3,767,784 | |
| 73.00p | +4.10 | +6.0% | 70.50p | 73.00p | 69.00p | 1,612,301 | |
| 68.90p | -2.10 | -3.0% | 71.50p | 74.00p | 68.90p | 1,083,209 | |
| 71.00p | +2.50 | +3.6% | 68.50p | 72.00p | 68.00p | 2,210,092 | |
| 68.50p | +2.00 | +3.0% | 66.50p | 70.00p | 66.00p | 1,267,836 | |
| 66.50p | -1.00 | -1.5% | 67.50p | 69.00p | 65.00p | 411,606 | |
| 67.50p | +1.50 | +2.3% | 67.00p | 69.00p | 65.00p | 477,724 | |
| 66.00p | -1.00 | -1.5% | 67.50p | 69.00p | 66.00p | 426,442 | |
| 67.00p | -1.00 | -1.5% | 68.00p | 69.00p | 64.00p | 1,676,665 | |
| 68.00p | -0.20 | -0.3% | 68.00p | 71.00p | 67.00p | 1,453,413 | |
| 68.20p | -0.80 | -1.2% | 68.50p | 69.00p | 67.00p | 672,520 | |
| 69.00p | -0.20 | -0.3% | 68.50p | 69.00p | 67.00p | 441,740 | |
| 69.20p | -0.30 | -0.4% | 70.50p | 72.00p | 67.00p | 939,396 | |
| 69.50p | +0.70 | +1.0% | 69.50p | 74.00p | 68.00p | 1,471,000 | |
| 68.80p | +0.80 | +1.2% | 68.00p | 71.00p | 67.00p | 736,008 | |
| 68.00p | -0.50 | -0.7% | 68.50p | 70.00p | 66.00p | 799,037 | |
| 68.50p | +2.50 | +3.8% | 66.00p | 70.00p | 65.93p | 1,700,898 |
Splits
2 splits since 2006 · LSE:AVCT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-100 | Consolidation | |
| 5-for-1 | Split |
- Ticker
- LSE:AVCT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LSE
- Currency
- GBX
What changed lately
Latest news release · Nov 19, 2026
AVA6207 Overcomes TOP1i Resistance
Latest earnings call · Oct 15, 2026
Avacta Group (LSE:AVCT) — Interim Results
Replay and transcript
Latest deck · March 2026
Investor Presentation (March 2026)
Investor deck · 25 slides
Latest news
AVA6207 Overcomes TOP1i Resistance
Nov 19, 2026
Closed 59.00p (+3.9%) on Nov 20, 2026
To Present pre|CISION® Dual Payload Candidate
Nov 4, 2026
Closed 57.50p (0.0%) on Nov 4, 2026
Jefferies Global Healthcare Conference
Nov 2, 2026
Closed 58.70p (-3.0%) on Nov 2, 2026
PFS Nearly Doubles with Faridoxorubicin Treatment
Oct 26, 2026
Closed 62.50p (-1.3%) on Oct 26, 2026
Avacta Highlights pre|CISION® Platform Data and Ongoing FOCUS-01 Trial Design with FAP-Exd (AVA6103)
Oct 23, 2026
Closed 63.30p (-1.2%) on Oct 23, 2026
Highlights pre|CISION® Platform Data
Oct 23, 2026
Closed 63.30p (-1.2%) on Oct 23, 2026
To Present on AVA6000 and AVA6103 at ESMO 2026
Oct 14, 2026
Closed 64.20p (+1.1%) on Oct 14, 2026
Notice of Interim Results Investor Meeting
Oct 12, 2026
Closed 64.00p (-2.3%) on Oct 12, 2026
Notice of Interim Results Investor Meeting
Oct 12, 2026
Closed 64.00p (-2.3%) on Oct 12, 2026
Results of Placing and Subscription
Oct 6, 2026
Closed 68.00p (-5.6%) on Oct 6, 2026
Avacta Group PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 70 in the last 12 months · 491 in all · newest Nov 19, 2026 · oldest 2003
- Calls
- 21 calls with a replay · 21 with a transcript · latest Oct 15, 2026
- Decks
- 27 decks · latest March 2026
Where Avacta Group PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:AVCT · Home listing · This page | LSE | United Kingdom | GBX |
| OTC:AVCTF | OTC | United States | USD |
| LS Exchange:A2ADP0 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2ADP0 | Lang & Schwarz | Germany | EUR |
| gettex:RTQ1 | gettex | Germany | EUR |
| Dusseldorf:RTQ1 | Dusseldorf | Germany | EUR |
| Frankfurt:RTQ1 | Frankfurt | Germany | EUR |
| Stuttgart:RTQ1 | Stuttgart | Germany | EUR |
Valuation
EV/sales 2,281× against a median of 45.3×: 7th lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- £257.8M GBP
- P/E
- Loss
- EV/sales
- 2,281×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 68.5×
- Gross margin
- 100.0%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 5.3×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Avacta Group PLC · LSE:AVCT | US$337.8M | US$337.2M | n/a | 2,281× | n/a | 68.5× | n/a | 5.3× | n/a |
| Alector, Inc. · NASDAQ:ALEC | US$347.6M | US$208.9M | 8.4× | 1.2× | 4.9× | 3.0× | 23.9% | 0.0× | 1.72 |
| Gongwin Biopharm Holdings Co., Ltd. · TPEX:6617 | US$347.3M | US$296.6M | n/a | 232× | n/a | 4.9× | −389.6% | 0.0× | n/a |
| AbClon, Inc. · KRX:174900 | US$346.1M | US$319.1M | n/a | 80.9× | n/a | 8.8× | −328.3% | 0.0× | n/a |
| Onconic Therapeutics, Inc. · KRX:476060 | US$344.4M | US$297.9M | 19.1× | 4.9× | n/a | 5.4× | 29.5% | 0.0× | n/a |
| Lyell Immunopharma, Inc. · NASDAQ:LYEL | US$339.3M | US$196.5M | n/a | 13,099× | n/a | 1.8× | n/a | 0.2× | 1.51 |
| Inovio Pharmaceuticals, Inc. · NASDAQ:INO | US$329.7M | US$7.56B | n/a | 25,303× | 3.4× | n/a | n/a | n/a | 0.70 |
| Larimar Therapeutics, Inc. · NASDAQ:LRMR | US$328.6M | US$204.7M | n/a | n/a | n/a | 3.2× | n/a | 0.1× | 1.48 |
| CytoDyn Inc. · OTC:CYDY | US$326.4M | US$345.8M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| C4 Therapeutics, Inc. · NASDAQ:CCCC | US$325.7M | US$175.5M | n/a | 5.4× | n/a | 1.4× | −282.2% | 0.2× | 1.46 |
| Laekna, Inc. · HKEX:2105 | US$322.8M | US$154.7M | n/a | 9.7× | n/a | 1.8× | −214.9% | 0.0× | n/a |
| Median of the others | US$334.5M | US$252.8M | 13.8× | 45.3× | 4.1× | 3.1× | −248.6% | 0.0× | 1.47 |
Forecasts
Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 90.50 GBX · Analysts' mean
- EPS, year to Dec 2026
- -0.072 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Brian Hahn | Company Secretary |
| David Liebowitz | Chief Medical Officer |
| Francis Wilson | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Mats Blom | Director |
| Patrick Vink | Director |
| Richard Hughes | Non-executive Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Avacta Group (LSE:AVCT) Q2 2026 Earnings Call | Thu, Oct 15, 2026 · 11:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) — Interim Results | Thu, Oct 15, 2026 · 11:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) Q4 2025 Earnings Call | Tue, May 19, 2026 · 9:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) — Phase 1b Faridoxorubicin (AVA6000) Salivary Gland Cancer Data Release | Wed, Dec 17, 2025 · 5:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) Q2 2025 Earnings Call | Tue, Sep 30, 2025 · 9:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) Q4 2024 Earnings Call | Fri, Jun 06, 2025 · 9:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) — Preliminary Results | Fri, Jun 06, 2025 · 6:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) Q2 2024 Earnings Call | Mon, Sep 30, 2024 · 9:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) — Investor Presentation | Mon, Sep 30, 2024 · 6:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) Q4 2023 Earnings Call | Tue, Apr 30, 2024 · 9:00 AM ET | Replay |
All 21 calls
| Call | When | Status |
|---|---|---|
| Avacta Group (LSE:AVCT) — Review of the AVA6000 clinical trial’s Phase 1a data | Wed, Dec 13, 2023 · 6:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) Q2 2023 Earnings Call | Thu, Sep 28, 2023 · 9:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) — Interim Results | Thu, Sep 28, 2023 · 6:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) — Post AGM Presentation and Investor Q&A | Wed, Jun 28, 2023 · 6:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) Q4 2022 Earnings Call | Tue, Apr 25, 2023 · 9:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) Q4 2021 Earnings Call | Wed, Apr 06, 2022 · 9:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) — Final Results | Wed, Apr 06, 2022 · 6:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) Q2 2021 Earnings Call | Thu, Sep 30, 2021 · 9:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) — Interim Results | Thu, Sep 30, 2021 · 5:30 AM ET | Replay |
| Avacta Group (LSE:AVCT) — Business Update and Q&A | Mon, Jun 21, 2021 · 5:00 AM ET | Replay |
| Avacta Group (LSE:AVCT) — Interim results for the 6 months ended 30 June 2020 | Mon, Sep 28, 2020 · 5:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Sep 30, 2025 | +20.6% |
| Quarter to Mar 31, 2025 | Jun 6, 2025 · Before open | −5.1% |
| Q2 2024 | Sep 30, 2024 | −12.6% |
| Q1 2023 | Apr 25, 2023 · Before open | −2.5% |
| Q2 2022 | Sep 30, 2022 · Before open | −3.5% |
| Q1 2022 | Apr 6, 2022 | +39.1% |
| Q2 2021 | Sep 30, 2021 | +2.9% |
| Q1 2021 | Apr 22, 2021 | −9.0% |
| Q4 2020 | Mar 29, 2021 | −8.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2026) | Investor deck | 25 slides | March 2026 |
| TD Cowen 46th Annual Healthcare Conference 2026 | Conference | 14 slides | March 2026 |
| Q2 2025 Earnings Presentation | Earnings | 9 slides | Sep 30, 2025 |
| Shareholder Meeting (July 2025) | Shareholder meeting | 18 slides | Jul 2, 2025 |
| Investor Presentation (March 2025) | Investor deck | 28 slides | March 2025 |
| Avacta Therapeutics — Investor Presentation (January 2025) | Investor deck | 34 slides | January 2025 |
| H1 2024 Earnings Presentation | Earnings | 28 slides | Sep 30, 2024 |
| FY2023 Earnings Presentation | Earnings | 27 slides | Apr 30, 2024 |
| H1 2023 Earnings Presentation | Earnings | 33 slides | Sep 28, 2023 |
| Shareholder Meeting (June 2023) | Shareholder meeting | 46 slides | Jun 28, 2023 |
All 27 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2022 Earnings Presentation | Earnings | 33 slides | Apr 25, 2023 |
| Investor Day (February 2023) | Investor day | 120 slides | Feb 23, 2023 |
| FY2021 Earnings Presentation | Earnings | 28 slides | Apr 6, 2022 |
| Investor Presentation (February 2022) | Investor deck | 23 slides | February 2022 |
| Immunotherapy World Congress 2021 | Conference | 21 slides | November 2021 |
| H1 2021 Earnings Presentation | Earnings | 25 slides | Sep 30, 2021 |
| Investor Presentation (June 2020) | Investor deck | 21 slides | Jun 5, 2020 |
| Investor Presentation (February 2020) | Investor deck | 13 slides | February 2020 |
| H1 2019 Earnings Presentation | Earnings | 22 slides | Apr 9, 2019 |
| Investor Day (February 2019) | Investor day | 67 slides | Feb 14, 2019 |
| Investor Day (February 2018) | Investor day | 41 slides | Feb 7, 2018 |
| H1 2016 Earnings Presentation | Earnings | 32 slides | Apr 25, 2016 |
| FY2013 Earnings Presentation | Earnings | 19 slides | Nov 16, 2013 |
| H1 2013 Earnings Presentation | Earnings | 19 slides | Apr 30, 2013 |
| FY2012 Earnings Presentation | Earnings | 16 slides | Oct 23, 2012 |
| H1 FY2012 Earnings Presentation | Earnings | 24 slides | Apr 25, 2012 |
| FY2011 Earnings Presentation | Earnings | 20 slides | Oct 25, 2011 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new Ordinary Shares Update: £12.5M · GBX 68 a share · Zeus Capital Limited +2 Dealers: Zeus Capital Limited (lead), Beech Hill Securities, Inc., Strand Hanson Buyers: Richard Hughes (£500,000, 735,294 Subscription Shares); Patrick Vink (£75,000, 110,294 Subscription Shares); David Bryant (£50,000, 73,529 Subscription Shares); Mats Blom (£35,000, 51,470 Subscription Shares); Zeus Capital Limited (180,001 Ordinary Shares for £122,400.68) Insiders: Directors Richard Hughes, Patrick Vink, David Byrant and Mats Blom subscribed for 970,587 new Ordinary Shares, approximately £660,000 Use of proceeds: Extend cash runway into Q2 2027 and fund the company through multiple pipeline value inflection points | Oct 6, 2026 | US$16.59M |
| Private placement of placing Shares Closed: £16M raised · GBX 63 a share · Zeus Capital Limited Dealers: Zeus Capital Limited (lead) Use of proceeds: Working capital to progress R&D programs into 2H 2026, including the faridoxorubicin Phase 1b trial and planned FAP-EXd Phase Ia trial | Nov 3, 2025 | US$21.46M |
| Private placement of new ordinary shares Announced: £3.25M · GBX 50 a share · Zeus Capital Limited Dealers: Zeus Capital Limited (lead) Use of proceeds: To settle the October 2025 quarterly repayment of the unsecured convertible bond | Aug 29, 2025 | US$4.38M |
| Private placement of new ordinary shares Announced: £3.25M · GBX 30 a share · Zeus Capital Limited +1 Dealers: Zeus Capital Limited (lead), Turner Pope Investments (TPI) Limited Use of proceeds: To settle the July quarterly repayment of the unsecured convertible bond due on 21 July 2025 | Jul 17, 2025 | US$4.36M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in GBP
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113.0K | 113.0K | 2.85M | 9.65M | 2.94M | 2.14M | 3.89M | 2.76M | 2.73M |
| Cost of revenue | 1.28M | 1.50M | 15.0K | 2.41M | 5.44M | 3.12M | 3.80M | 2.93M | 2.52M |
| Gross profit | 113.0K | 113.0K | 2.84M | 7.24M | -2.50M | -973.0K | 86.1K | -164.0K | 211.0K |
| Research and development | 16.9M | 14.3M | 13.1M | 11.1M | 13.5M | 8.89M | 5.55M | 2.73M | 2.03M |
| Selling, general and administrative | 9.24M | 12.0M | 2.91M | 2.29M | 4.94M | 1.05M | 8.46M | 8.52M | 7.18M |
| Operating income | -30.3M | -32.6M | -22.0M | -25.5M | -29.1M | -16.9M | -12.7M | -9.45M | -7.97M |
| Depreciation and amortization | 1.28M | 1.44M | 1.28M | 3.01M | 2.38M | 2.15M | 2.79M | 2.03M | 1.58M |
| EBITDA | -29.0M | -31.1M | -20.7M | -22.5M | -26.7M | -14.7M | -9.93M | -7.41M | -6.39M |
| Interest expense | 7.05M | 10.1M | 15.3M | 2.70M | 128.0K | 89.0K | 69.2K | 0 | 0 |
| Income before tax | -37.9M | -29.0M | -31.1M | -41.6M | -29.2M | -18.9M | -12.7M | -10.4M | -7.89M |
| Income tax | -1.64M | 444.0K | 1.98M | -4.66M | -2.82M | -2.46M | -1.72M | -1.56M | -1.53M |
| Net income | -38.4M | -52.8M | -24.9M | -36.9M | -26.3M | -18.9M | -11.0M | -8.83M | -6.37M |
| Earnings per share, basic | -0.10 | -0.16 | -0.09 | -0.14 | -0.11 | -0.08 | -0.09 | -0.13 | -0.09 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 16.9M | 12.9M | 16.6M | 41.8M | 26.2M | 27.9M | 8.79M | 8.79M | 5.22M | 9.17M |
| Short-term investments | 20.0M | 4.00M | ||||||||
| Receivables | 6.34M | 3.38M | 4.49M | 3.72M | 4.61M | 1.76M | 3.69M | 3.69M | 370.0K | 2.48M |
| Inventory | 0 | 2.58M | 1.68M | 189.0K | 248.0K | 156.0K | 156.0K | 187.0K | 158.0K | |
| Current assets | 23.2M | 40.2M | 28.0M | 55.6M | 34.7M | 53.3M | 13.5M | 13.5M | 8.20M | 15.8M |
| Property, plant and equipment | 4.34M | 4.79M | 3.08M | 3.05M | 3.45M | |||||
| Goodwill | 1.54M | 1.54M | 17.0M | 14.2M | 1.54M | 2.31M | 3.83M | 3.83M | 3.83M | 4.66M |
| Total assets | 29.4M | 48.3M | 73.2M | 92.6M | 47.0M | 67.5M | 28.4M | 28.4M | 23.5M | 31.6M |
| Accounts payable | 8.95M | 2.80M | 3.73M | 2.49M | 561.0K | 856.0K | 698.0K | 698.0K | 831.0K | 645.0K |
| Current liabilities | 26.2M | 37.3M | 45.1M | 67.6M | 4.37M | 3.78M | 1.96M | 1.96M | 2.04M | 1.66M |
| Long-term debt | 0 | 219.0K | 0 | |||||||
| Total debt | 14.9M | 22.9M | 23.5M | 62.9M | 1.70M | 2.04M | 823.0K | 823.0K | ||
| Total liabilities | 26.9M | 39.0M | 51.4M | 74.2M | 5.78M | 5.53M | 2.60M | 2.60M | 2.04M | 1.66M |
| Shareholders' equity | 2.48M | 9.28M | 21.8M | 18.4M | 41.2M | 61.9M | 25.8M | 25.8M | 21.4M | 29.9M |
| Shares outstanding | 399.9M | 326.9M | 272.7M | 255.4M | 249.6M | 225.7M | 120.4M | 65.5M | 68.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -24.8M | -23.6M | -14.9M | -16.4M | -20.5M | -10.6M | -13.0M | -5.47M | -4.24M |
| Capital spending | -53.0K | -339.0K | -1.26M | -594.0K | -1.31M | -1.67M | -2.53M | -2.52M | -2.13M |
| Free cash flow | -24.8M | -23.9M | -16.1M | -17.0M | -21.8M | -12.3M | -15.5M | -7.99M | -6.37M |
| Cash from investing | 9.90M | -1.43M | -9.00M | -25.0M | 18.7M | -21.9M | -2.53M | 1.48M | 3.87M |
| Cash from financing | 13.6M | 26.1M | -1.30M | 56.9M | 232.0K | 51.6M | 19.1M | 45.0K | 14.0K |
| Share buybacks | 45.0K | 14.0K | |||||||
| Change in cash | 3.98M | 1.15M | -25.2M | 15.6M | -1.70M | 39.1M | 1.29M | -3.95M | -355.0K |
Cap table
Built by 6ix from Avacta Group PLC’s releases · as of Nov 3, 2025
- Common shares
- 437,633,189
- Fully diluted
- 437,633,189
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 437,633,189 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 437,633,189 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Brian Hahn | Company Secretary · Since at least Oct 27, 2025 |
| Craig Slater | Chief Operating Officer · Since Dec 23, 2013 · Appointed, no departure found |
| David Liebowitz | Chief Medical Officer · Since at least Jul 1, 2025 |
| Francis Wilson | Chief Scientific Officer · Since at least Feb 9, 2026 |
| Mats Blom | Director · Since at least Sep 14, 2026 |
| Patrick Vink | Director · Since Jul 8, 2026 |
| Philippe Cotrel | Chief Commercial Officer · Since Jan 25, 2016 · Appointed, no departure found |
| Richard Hughes | Non-executive Director · Since at least May 29, 2026 |
Log in to ask 6ix AI your own questions about Avacta Group PLC.